Compare ONEW & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ONEW | MOLN |
|---|---|---|
| Founded | 2014 | 2004 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Auto & Home Supply Stores | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 155.3M | 144.0M |
| IPO Year | 2019 | 2021 |
| Metric | ONEW | MOLN |
|---|---|---|
| Price | $10.65 | $4.34 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $16.75 | $8.38 |
| AVG Volume (30 Days) | ★ 105.2K | 2.1K |
| Earning Date | 04-30-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.77 | N/A |
| Revenue | ★ $1,872,334,000.00 | N/A |
| Revenue This Year | $0.30 | N/A |
| Revenue Next Year | $3.14 | $374.07 |
| P/E Ratio | $4.00 | ★ N/A |
| Revenue Growth | ★ 5.62 | N/A |
| 52 Week Low | $8.12 | $3.36 |
| 52 Week High | $17.92 | $5.36 |
| Indicator | ONEW | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 55.81 | 51.67 |
| Support Level | $10.23 | $4.04 |
| Resistance Level | $12.51 | $4.50 |
| Average True Range (ATR) | 0.68 | 0.13 |
| MACD | 0.19 | 0.05 |
| Stochastic Oscillator | 56.52 | 72.47 |
OneWater Marine Inc is a recreational marine retailer in the United States. The company operates in two segments: Dealership and Distribution. The Dealership segment is involved in selling new and pre-owned boats. It also arranges financing and insurance products, provides repairs and maintenance services, offers marine-related parts and accessories, and supplies slip and storage accommodations at certain locations. The Distribution segment focuses on the manufacturing, assembly, and distribution of marine-related products. These products are supplied to distributors, box retailers, and online retailers through a network of warehouses and distribution centers. The company generates the majority of its revenue from the Dealership segment.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.